Skip to main content

Table 1 Studies of indacaterol included in the study-level pooled analysis (all studies) and patient-level analysis (B2335S and B2356)

From: Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches

Design

Patients

Indacaterol dose, μg

Pbo

For

Sal

Tio

  

18.75

37.5

75

150

300

600

    

Cross-over, 14-day

96

    

144

 

72

 

72

 

Parallel-group, 52-week

1732

    

437

428

432

435

  

Parallel-group 26-week

2059

  

130

420

418

123

425

123

 

420

Crossover, 14-day

68

    

66

 

66

 

65

 

Parallel-group, 12-week

416

   

211

  

205

   

Parallel-group, 12-week

347*

   

114

116

 

117

   

Parallel-group, 26-week

563

   

188

188

 

187

   

Parallel-group, 26-week

1002

   

333

  

335

 

334

 

Parallel-group, 12-week

323

  

163

   

160

   

Parallel-group, 12-week

318

  

159

   

159

   

Parallel-group, 12-week

552

92

91

94

92

  

91

 

92

 
 

7476

92

91

546

1358

1369

551

2249

558

563

420

  1. All studies were placebo-controlled. Values are numbers of patients (the sum of totals across the columns for indacaterol dose and comparators is greater than the total number of patients randomized due to the inclusion of cross-over studies). *Asian patients; 73 morning dosing vs 71 evening dosing. Pbo = placebo; For = formoterol 12 μg bid; Sal = salmeterol 50 μg bid; Tio = tiotropium 18 μg qd